[{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "website": "https://centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.", "fullTimeEmployees": 114, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 48, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1227787, "exercisedValue": 0, "unexercisedValue": 48016716}, {"maxAge": 1, "name": "Mr. John J. Crowley CPA", "age": 50, "title": "CFO & Principal Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 682031, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 43, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 768575, "exercisedValue": 0, "unexercisedValue": 6312665}, {"maxAge": 1, "name": "Mr. Raphael  Deferiere CPA", "age": 45, "title": "Chief Accounting Officer & Principal Accounting Officer", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 53, "title": "Chief Technology & Quality Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 56, "title": "Chief People Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D.", "age": 53, "title": "Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mario Alberto Accardi Ph.D.", "title": "President of the Orexin Program", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Charlene  Stoudt", "title": "Senior Vice President of Clinical Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.68, "open": 25.61, "dayLow": 25.0701, "dayHigh": 25.965, "regularMarketPreviousClose": 25.68, "regularMarketOpen": 25.61, "regularMarketDayLow": 25.0701, "regularMarketDayHigh": 25.965, "payoutRatio": 0.0, "beta": 1.56, "forwardPE": -15.635802, "volume": 464794, "regularMarketVolume": 464794, "averageVolume": 1573625, "averageVolume10days": 1542940, "averageDailyVolume10Day": 1542940, "bid": 18.4, "ask": 32.1, "bidSize": 2, "askSize": 2, "marketCap": 3700098560, "fiftyTwoWeekLow": 9.6, "fiftyTwoWeekHigh": 30.58, "allTimeHigh": 30.58, "allTimeLow": 2.885, "priceToSalesTrailing12Months": 246.67323, "fiftyDayAverage": 25.8763, "twoHundredDayAverage": 18.3416, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3277608704, "profitMargins": 0.0, "floatShares": 80094609, "sharesOutstanding": 146075743, "sharesShort": 5662349, "sharesShortPriorMonth": 5921306, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0383, "heldPercentInsiders": 0.0043099998, "heldPercentInstitutions": 0.87448996, "shortRatio": 3.27, "shortPercentOfFloat": 0.0444, "impliedSharesOutstanding": 146075743, "bookValue": 2.244, "priceToBook": 11.287879, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -242698000, "trailingEps": -1.89, "forwardEps": -1.62, "enterpriseToRevenue": 218.507, "enterpriseToEbitda": -15.353, "52WeekChange": 0.57064223, "SandP52WeekChange": 0.17354333, "quoteType": "EQUITY", "currentPrice": 25.33, "targetHighPrice": 62.0, "targetLowPrice": 30.0, "targetMeanPrice": 38.76923, "targetMedianPrice": 36.0, "recommendationKey": "none", "numberOfAnalystOpinions": 13, "totalCash": 246214000, "totalCashPerShare": 1.831, "ebitda": -213490000, "totalDebt": 118259000, "quickRatio": 10.247, "currentRatio": 10.565, "totalRevenue": 15000000, "debtToEquity": 39.214, "revenuePerShare": 0.113, "returnOnAssets": -0.2526, "returnOnEquity": -0.60621, "grossProfits": 15000000, "freeCashflow": -116738248, "operatingCashflow": -180810000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -14.25333, "financialCurrency": "USD", "symbol": "CNTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "epsTrailingTwelveMonths": -1.89, "epsForward": -1.62, "epsCurrentYear": -1.343, "priceEpsCurrentYear": -18.860758, "fiftyDayAverageChange": -0.5463009, "fiftyDayAverageChangePercent": -0.021112017, "twoHundredDayAverageChange": 6.9883995, "twoHundredDayAverageChangePercent": 0.3810136, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-05-28", "prevName": "Centessa Pharmaceuticals Limited", "nameChangeDate": "2025-12-26", "cryptoTradeable": false, "regularMarketChangePercent": -1.36293, "regularMarketPrice": 25.33, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1766787850, "regularMarketTime": 1766782800, "exchange": "NMS", "messageBoardId": "finmb_704505677", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1622208600000, "postMarketChangePercent": 0.0, "postMarketPrice": 25.33, "postMarketChange": 0.0, "regularMarketChange": -0.35, "regularMarketDayRange": "25.0701 - 25.965", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1573625, "fiftyTwoWeekLowChange": 15.73, "fiftyTwoWeekLowChangePercent": 1.6385416, "fiftyTwoWeekRange": "9.6 - 30.58", "fiftyTwoWeekHighChange": -5.25, "fiftyTwoWeekHighChangePercent": -0.17168084, "fiftyTwoWeekChangePercent": 57.064224, "earningsTimestamp": 1762349400, "earningsTimestampStart": 1762349400, "earningsTimestampEnd": 1762349400, "isEarningsDateEstimate": false, "displayName": "Centessa Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]